Clinical trial
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.
NCT01510158 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.
- Lead sponsor
- Ardea Biosciences, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- August 31, 2014
- Enrollment
- 607 (actual)
- Sites
- 165
Conditions
As the registry lists them; a condition with its own page is linked.